--Oculis Holding AG, a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that it ...

About OCS-05 OCS-05 is a serum-glucose corticoid kinase-2 (SGK-2) activator with the potential to become a neuroprotective therapy for acute optic neuritis and other neuro-ophthalmic diseases.

Quantifying axonal loss after optic neuritis with optical coherence tomography. Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society, 59 ...

There were 5344 cases of optic neuritis in the database. As expected, multiple sclerosis was the most common disease among patients with optic neuritis, found in 20.6% of cases, followed by NMOSD ...

Key takeaways: The phase 2 ACUITY trial evaluated OCS-05 at 2 mg/kg/day and 3 mg/kg/day. The trial met safety and efficacy endpoints. OCS-05 met safety and efficacy endpoints in the treatment of ...

Casserly CC, et al. Effect of fampridine SR on individuals with multiple sclerosis and poor recovery from optic neuritis: A pilot study. Presented at: ACTRIMS; Feb. 27-March 1, 2025; West Palm Beach.

Privosegtor is a novel peptidomimetic small molecule candidate with the potential to become a first-in-class neuroprotective therapy for acute optic neuritis and other neuro-ophthalmic diseases.

ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and ...